Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.53 USD | +2.49% | +0.89% | -48.05% |
Apr. 26 | Adherium Seeks to Raise AU$8.4 Million Via Placement, Entitlement Offer; Shares Fall 24% | MT |
Apr. 18 | EHealth Reaffirms 2024 Guidance | MT |
Strengths
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.17 for the 2024 fiscal year.
- The company appears to be poorly valued given its net asset value.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Multiline Insurance & Brokers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-48.05% | 132M | C- | ||
-2.06% | 61.97B | C | ||
+4.10% | 51.16B | B- | ||
+4.04% | 25.66B | C+ | ||
+14.55% | 23.24B | C | ||
+26.59% | 9.56B | - | ||
+13.76% | 5.81B | - | ||
-4.12% | 4.02B | B | ||
+1.30% | 1.99B | C+ | ||
+11.16% | 1.76B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- EHTH Stock
- Ratings eHealth, Inc.